Last updated on July 2019

A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3K Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor


Brief description of study

The purpose of this study is to assess the efficacy of INCB050465 in terms of objective response rate (ORR) in subjects with mantle cell lymphoma (MCL) that is relapsed or refractory after at least 1 but no more than 3 prior systemic treatment regimens.

 

Clinical Study Identifier: TX154659

Find a site near you

Start Over

HOPITAL SAINT LOUIS

Located in: Paris, France
5.72miles
  Connect »

AVICENNE HOSPITAL

Located in: Bobigny, France
7.71miles
  Connect »

CENTRE HOSPITALIER DE VERSAILLES

Located in: LE CHESNAY, France
8.7miles
  Connect »